GlobeNewswire Inc.··NaCullinan's CD19 T Cell Engager Shows Promise in Autoimmune Disease
Cullinan Therapeutics to present Phase 1 data for CLN-978 at EULAR 2026, demonstrating favorable safety and B cell depletion in treatment-refractory rheumatoid arthritis and lupus.
CGEMbiopharmaceuticalPhase 1 clinical trial